Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23515142 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Tocilizumab;   Drug: Adalimumab;   Drug: Placebo to tocilizumab;   Drug: Placebo to adalimumab

Indicates status has not been verified in more than two years